Therapy for urogenital disorders in postmenopausal women
https://doi.org/10.21518/2079-701X-2018-13-155-158
Abstract
Data are presented on the stages of aging of the female reproductive system and the symptoms developing in these age periods. It is noted that the pathogenesis of development of urogenital disorders are connected with decrease in the level of estrogens in the peri- and postmenorausal period. Effective therapy for women with vaginal atrophy is the administration of estriol preparations (Оvestin) in the form of a cream or vaginal suppositories.
About the Authors
T. V. Ovsyannikova
Russian Peoples’ Friendship University
Russian Federation
Russian Federation
I. A. Kulikov
Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
References
1. Menopausal hormone therapy and health preservation of middle-aged women. Moscow, 2014.
2. Harlow SD, Gass M, Hall JD et al. Executive summary of the Stages of Reproductive Aging Workshop +10: addressing the unfinished agenda of staging reproductive aging. Climacteric, 2010, 15: 105-114.
3. Avis N.E., Crawford S.L., Greendale G. et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern MED, 2015, 175: 513-539.
4. Randolf J, Zheng H, Sower MR, Change in FSH and estradiol across the menopausal transition: effect of age at final menstrual period. J Clin Endocrinol Metab, 2011, 96: 746-754.
5. http://www.statdata.ru/spg_reg_rf.
6. Baber RJ, Panay N, Fenton A. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric, 2016. 19 (2): 109-150. doi.org/10.3109/13697137.2015.1129166.
7. The 2017 hormone therapy position statement of The North American Menopause Society Menopause. The Journal of The North American Menopause Society, 2017, 24(7): 728-753. doi. org/10.1097/GME.0000000000000921. 8.
8. Robinson D, Ioozs-Hobson P, Cardoso L. The effect of hormones on the lower urinary tract. Menopause, 2013.19.155-162.
9. Gynecology. National guidelines (under the editorship of Savelyeva GM, Sukhikh GT, Serov VN, et al). Moscow: GEOTAR-Media. 2017: 275-284.
10. Ovsyannikova TV, Makarov IO, et al. Local therapy of urogenital disorders in peri- and postmenopausal women. Akusherstvo, Ginekologiya i Reproduktsiya, 2010, 4 (3): 25-28.
11. Balan VE, Kovaleva LA, Tikhomirova EV. Genitourenal or urogenital syndrome. Possibilities of long-term therapy. Meditsinsky Sovet, 2016, 12: 98-101.
12. Rahn D, Ward RV, Sanses TV et al. Sosiety of Gynecologic Surgeons Systematic Review Group. Vaginal estrogen use in postmenopausal women with pelvic floor disordes. Urogynecol, J, 2015, 26: 3-13.
13. Rees M, Perez-Lopez FR, Ceasul I et al. EMAS clinical guide: low-dose vaginal estrogens for postmenopausal atrophy. Maturitas, 2012, 73: 171-174.
14. Beber RJ, Panay N, Fenton A. IMS Recommendations, Climacteris, 2016.
Review
For citations:
Ovsyannikova TV, Kulikov IA. Therapy for urogenital disorders in postmenopausal women. Meditsinskiy sovet = Medical Council. 2018;(13):155-158. (In Russ.) https://doi.org/10.21518/2079-701X-2018-13-155-158
Views:
649
Email this article 